National Cancer Institute (NCI): Anus Neoplasms trials

The registry lists 21 Anus Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 12Phase 2 10Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated CancersCompletedNCT04432597Phase 1/2Results posted
• Combination Immunotherapy in Subjects With Advanced HPV Associated MalignanciesCompletedNCT04287868Phase 1/2Results posted
• M7824 in Subjects With HPV Associated MalignanciesCompletedNCT03427411Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02408861Phase 1Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerActive, not recruitingNCT02314169Phase 2Results posted
• T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated CancersCompletedNCT02280811Phase 1/2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated CancersCompletedNCT01585428Phase 2Results posted
• Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal CancerTerminatedNCT01324141Phase 1Results posted
• Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerActive, not recruitingNCT04929028Phase 2
• A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon CancersCompletedNCT04708470Phase 1/2
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabWithdrawnNCT04536922Phase 2
• EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer PatientsActive, not recruitingNCT04444921Phase 3
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal CancerActive, not recruitingNCT03233711Phase 3
• Anal Cancer Screening StudyCompletedNCT00914537
• Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated ControlsActive, not recruitingNCT00867464
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal NeoplasiaCompletedNCT00052897Phase 1/2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Vaccine Therapy in Treating Patients With Advanced or Recurrent CancerCompletedNCT00019110Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1